Invokana bags FDA approval by Anna Smith | Oct 1, 2019 | News | 0 The treatment has been approved to reduce the risk of hospitalisation for heart failure in certain patients with type II diabetes. Read More
Farxiga cuts hospitalisation for heart failure or CV death, study shows by Selina McKee | Sep 25, 2018 | News | 0 AstraZeneca has unveiled new data showing a statistically-significant reduction in hospitalisation for heart failure or cardiovascular (CV) death in a broad population of patients with type II diabetes taking Farxiga. Read More